Immunovant
Market cap $6.87B 206.9M shares (10-Q, Nov 3, 2026) × $33.21 close Nov 17, 2026
Most recent annual filing: 2026-05-20
Pipeline (4 active programs)
Discontinued (3)
- imeroprubart — Sjögren's Disease · evolving landscape and recent field data; unlikely to advance beyond ongoing Phase 2
- imeroprubart — Cutaneous Lupus Erythematosus · missed primary endpoint; competitive landscape
- batoclimab — Thyroid Eye Disease · Company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402
Capital (as filed)
- Cash
- $722M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$83.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $722M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-11-09 S-3ASR · Shelf registration up to $150M aggregate
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-10 UPDATE: Immunovant (IMVT) - The Placebo Test, Passed (With Footnotes) ★ Distilled Pro
- 2026-09-23 UPDATE: Immunovant (IMVT) - The First Placebo Test Comes Back Empty 🔒 Paid
- 2026-08-07 UPDATE: Immunovant (IMVT) - The Quarter Where the Burn Got Real
- 2026-05-20 UPDATE: Immunovant (IMVT) - The Bio-Better Bet Cashes Its First Check 🔒 Paid
- 2026-04-04 UPDATE: Immunovant (IMVT) - The Bato Swan Song and the Pivot to Purity 🔒 Paid
- 2026-02-07 UPDATE: Immunovant (IMVT) - Quarterly Update 🔒 Paid
- 2026-02-02 Immunovant (IMVT): Scientific Deep Dive for IMVT-1402 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Immunovant, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-02 Buy core Immunovant (IMVT): Scientific Deep Dive for IMVT-1402 and Pipeline Products IMVT-1402's engineered fix for batoclimab's albumin/LDL safety flaws creates an asymmetric entry point despite HanAll legal risk, with strong Phase 1 data and a billion-dollar cash runway.
- 2026-02-07 Buy core UPDATE: Immunovant (IMVT) - Quarterly Update Q3 earnings confirm the thesis is intact: $1B cash fortress removes dilution risk, all six IMVT-1402 trials enrolling on schedule, and HanAll legal situation remains stable.
- 2026-04-04 Buy core UPDATE: Immunovant (IMVT) - The Bato Swan Song and the Pivot to Purity Batoclimab's Phase 3 TED data validated the anti-FcRn mechanism while confirming the lipid safety flaw, clearing the deck for IMVT-1402 and creating a buying opportunity if the market misreads the mixed headlines as a company failure.
- 2026-05-20 Buy core UPDATE: Immunovant (IMVT) - The Bio-Better Bet Cashes Its First Check IMVT-1402's first efficacy data in sick patients showed clean safety and strong ACR response rates, partially de-risking the bear case, though the stock is less attractively priced and HanAll posture hardened to pre-litigation.
- 2026-08-07 Buy core UPDATE: Immunovant (IMVT) - The Quarter Where the Burn Got Real No new data or timeline slips across six trials, HanAll escalation paused for a full quarter, but burn accelerated to $124M/quarter and management flagged potential unbudgeted late-stage expansion, making the dilution gap data-contingent rather than nonexistent.
- 2026-09-23 Hold UPDATE: Immunovant (IMVT) - The First Placebo Test Comes Back Empty IMVT-1402 missed its primary endpoint in CLE — the first blinded placebo-controlled test — concentrating all near-term binary risk on D2T RA Period 2, making this a wait-for-the-placebo-print moment rather than a buy-the-dip one.
- 2026-11-10 Buy core UPDATE: Immunovant (IMVT) - The Placebo Test, Passed (With Footnotes) IMVT-1402 600mg beat placebo in the D2T RA withdrawal test and the failed 300mg arm validates the depth thesis for Graves' disease, repairing the dented thesis and making this a reasonable point to rebuild a Graves'-driven position.
- Long call · opened Feb 2, 2026 at $26.08 · +27.3% vs XBI +14.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (17)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 23, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026S-3ASRAutomatic shelf registration→ BD update
- Nov 9, 2026ReleaseRoivant 2Q 2026 Earnings Call→ BD update
- Nov 9, 2026ReleaseImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026→ BD update
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD update
- Nov 9, 202610-QQuarterly report→ BD update
- Oct 21, 2026ReleaseImmunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
- Sep 23, 2026ReleaseImmunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus→ BD updateIMVT-1402's proof-of-concept in cutaneous lupus missed its primary endpoint (CLASI-A at Week 12, n=57), and Immunovant is killing the CLE program — but the safety profile held clean and the five remaining indications are unaffected. The question is whether this is a CLE-specific whiff or a signal about the "depth-of-IgG-suppression" thesis in skin disease.BD extracted 2 program updates from this document → IMVT pipeline
- Sep 3, 20268-KCurrent report: shareholder vote
- Sep 2, 2026Release2026 Annual Meeting of Stockholders
- Aug 6, 2026ReleaseImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026via aggregator
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly reportBD extracted 2 program updates from this document → IMVT pipeline
- Jul 23, 2026ReleaseImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026via aggregator
- Jul 22, 2026DEFA14AProxy soliciting material
- Jul 22, 2026DEF 14AProxy statement
- May 20, 20268-KCurrent report: results of operations · EX-99.1
- May 20, 202610-KAnnual report
2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 22, 2026ARSAnnual report to shareholders